Physician profile
Lora Lonidier
NPI 1235210170
$4,032.85
in general payments reported to CMS, 2019-2025
22 companies · $1,519 in 2025
The $1,519 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $500 · 2022: $201 · 2023: $642 · 2024: $1,171 · 2025: $1,519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,231 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,231.32 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $590.25 | 2021-2025 | Airsupra, Breztri, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $578.86 | 2021-2025 | Ofev, Jascayd |
| Mallinckrodt Hospital Products INC. | $558.74 | 2021-2025 | Acthar |
| Regeneron Healthcare Solutions, INC. | $310.42 | 2021-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $280.62 | 2021-2023 | Uptravi, Opsumit |
| Takeda Pharmaceuticals U.S.A., INC. | $272.29 | 2021-2025 | Glassia |
| Abbott Laboratories | $259.88 | 2024 | Freestyle Libre |
| Genzyme Corporation | $227.26 | 2024-2025 | |
| Verona Pharma, INC. | $173.72 | 2025 | Ohtuvayre |
| United Therapeutics Corporation | $140.98 | 2022-2025 | Tyvaso, Tyvaso, Orenitram |
| Mylan Specialty L.P. | $118.57 | 2023-2024 | Yupelri |
| Access Pro Medical, LLC | $111.37 | 2023 | Matriderm |
| Merck Sharp & Dohme LLC | $77.52 | 2024-2025 | Zerbaxa |
| Baxter Healthcare | $69.13 | 2023-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Glaxosmithkline, LLC. | $64.16 | 2021-2024 | Trelegy Ellipta |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $51.88 | 2025 | Purified Cortrophin Gel |
| Grifols USA, LLC | $42.57 | 2025 | Prolastin-C Liquid |
| Amgen INC. | $28.40 | 2023-2025 | Tezspire |
| Avadel Cns Pharmaceuticals, LLC | $26.22 | 2025 | Lumryz |
| Ambu INC. | $19.92 | 2022 | |
| Boston Scientific Corporation | $16.56 | 2021 | |
| Philips North America LLC | $13.53 | 2025 | Vest Therapy Und |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lora Lonidier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.